Reata Pharmaceuticals Inc

$29.63 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.

Stock Analysis

last close $29.63
1-mo return 14.4%
3-mo return 13.4%
avg daily vol. 511.12T
52-week high 153.41
52-week low 20.24
market cap. $908M
forward pe -
annual div. -
roe -122.2%
ltg forecast -
dividend yield -
annual rev. $11M
inst own. 86.5%
baraka

Subscribe now for daily local and international financial news

Subscribe